What question did this study set out to answer?

The research aims to investigate how low-dose simvastatin affects pancreatic cancer cells through mitochondrial autophagy.

January 21, 2026Cellular Oncology0 citationsOpen Access

View Full Paper

Low-dose Simvastatin protects pancreatic cancer cells by promoting mitochondrial autophagy through TFEB

ZWZhiliang WangSoochow University DWD P WuSoochow University YZY. ‐S. ZhangSoochow University

Key Points

The research aims to investigate how low-dose simvastatin affects pancreatic cancer cells through mitochondrial autophagy.
Examined the effects of low-dose simvastatin on pancreatic cancer cells.
Assessed mitochondrial autophagy levels and related pathways.
Analyzed the role of TFEB in the modulation of autophagy.
Low-dose simvastatin enhances mitochondrial autophagy in pancreatic cancer cells.
TFEB is identified as a key regulator in this process.
Findings suggest suboptimal efficacy of simvastatin may relate to mitochondrial dynamics.

Abstract

These findings may explain one of the reasons for the suboptimal efficacy of simvastatin in the treatment of pancreatic cancer, while also providing new insights for research on the antitumor effects of statins.

Ask AI

Helpful

Bookmark

View Full Paper

Ask AI

Helpful

Bookmark

View Full Paper

Low-dose Simvastatin protects pancreatic cancer cells by promoting mitochondrial autophagy through TFEB

Key Points

Abstract

Cite This Study

Also Consider

Also Consider